A Phase 2 Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Patients with relapsed/refractory non-Hodgkin lymphomas remain a population of unmet medical need. Histone deacetylase inhibitors (HDACIs) and proteasome inhibitors have shown synergistic interactions pre-clinically in several B-cell malignancies. This phase 2 trial examined the combination of the proteasome inhibitor bortezomib and the HDACI vorinostat in patients with relapsed/refractory diffuse large B-cell lymphoma or mantle cell lymphoma. The results of this trial reveal a modest overall response rate.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 5, 2018 Category: Hematology Authors: Victor Yazbeck, Danielle Shafer, Edward B. Perkins, Domenico Coppola, Lubomir Sokol, Kristy L. Richards, Thomas Shea, Jia Ruan, Samir Parekh, Roger Strair, Christopher Flowers, David Morgan, Maciej Kmieciak, Prithviraj Bose, Amy Kimball, Ashraf Z. Badros, Tags: Original Study Source Type: research